Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded down 18% on Wednesday . The company traded as low as GBX 4.60 ($0.06) and last traded at GBX 4.84 ($0.06). 61,560,121 shares traded hands during mid-day trading, an increase of 142% from the average session volume of 25,488,205 shares. The stock had previously closed at GBX 5.90 ($0.07).
ImmuPharma Stock Performance
The stock has a market cap of £20.74 million, a price-to-earnings ratio of -498.00 and a beta of 1.53. The company has a 50-day simple moving average of GBX 1.92 and a two-hundred day simple moving average of GBX 1.78.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- Upcoming IPO Stock Lockup Period, Explained
- 3 Steel Stocks Soaring After Tariff Announcements
- What is a Stock Market Index and How Do You Use Them?
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
- Dividend Capture Strategy: What You Need to Know
- Why Salesforce Stock Could Be at Fresh Highs by February
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
